StockWatch
·

Concord Drugs Ltd Q1 FY26 Results

CONCORDQ1 FY26 Results
Filing
MetricValue ( Cr)vs Q4 FY25
Revenue13.6130.9%
Total Income13.6130.9%
Expenditure13.4530.1%
PBT0.16173.3%
Net Profit0.12202.1%
OPM7.47%2.56pp
NPM0.87%0.49pp
EPS0.12200.0%
View full financials

Informational and educational content only. Not investment advice.